Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Time up for EU states on breast implants directive:

This article was originally published in Clinica

Executive Summary

This week's issue of Clinica (No 1068) coincides with the August 1 deadline by which all EU member states should have transposed into their national laws the EU Breast Implants Directive in readiness for the regulations to take effect on September 1. The Directive 2003/12/EC imposes stricter manufacturing requirements on breast implants by upgrading them from class IIb (medium-to-high) risk to class III (high risk), ensuring that the notified body will have to review the manufacturer's design dossiers. Directive 2003/12/EC on the reclassification of breast implants was adopted on February 3 and published in the Official Journal of the European Union on February 4. Breast implants that are placed on the market before September 1 2003 will need to be assessed against the stricter requirements by March 1 2004.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT063114

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel